Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VK 2735 (Primary)
Indications Obesity; Weight loss
Focus Therapeutic Use
Acronyms VENTURE
Sponsors Viking Therapeutics

Most Recent Events

11 Feb 2026 According to a Viking Therapeutics media release, in December 2025, company has held an end-of-Phase 2 meeting with the FDA to discuss potential next steps for oral VK2735.
12 Jan 2026 According to a Viking Therapeutics media release, data from the trial were presented in Obesity, the peer-reviewed journal of The Obesity Society
12 Jan 2026 Results presented in the Viking Therapeutics Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com